vascular endothelial growth factor receptor 2; VEGFR-2; kinase insert domain receptor; protein-tyrosine kinase receptor Flk-1; CD309 (KDR, FLK1)

Function

• receptor for VEGF or VEGFC
• has a tyrosine-protein kinase activity
• the VEGF-kinase ligand/receptor signaling system plays a role in vascular development & regulation of vascular permeability
• interacts with SHB upon VEGF activation
• Flk1 & Flt1 bind VEGF with high affinity & are required for embryonic & definitive hematopoiesis

Structure

• belongs to the protein kinase superfamily, Tyr protein kinase family, CSF-1/PDGF receptor subfamily
• contains 7 Ig-like C2-type domain (immunoglobulin-like)
• contains 1 protein kinase domain

Compartment

membrane

Expression

• expressed in developing blood islands of primitive streak stage embryos
• expressed in posterior splanchnopleure & fetal liver hematopoietic precursors

Pathology

• interacts with HIV-1 Tat
• in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions

Pharmacology

• ramucirumab used for treatment of advanced gastric cancer,
• gastroesophageal junction adenocarcinoma & metastatic colorectal cancer inhibits VEGFR2 via its ligand-binding site

More general terms

• vascular endothelial growth factor [VEGF] receptor
• CD antigen

Database

• Kegg: http://www.genome.jp/dbget-bin/www_bget?hsa:3791
• OMIM: https://mirror.omim.org/entry/191306
• UniProt: http://www.uniprot.org/uniprot/P35968.html